Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit remains negative
Q1 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.
Context
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (26.27K) | +99.8% |
| FY2023 | 2023-12-31 | (13.36M) | -11544.6% |
| FY2022 | 2022-12-31 | 116.72K | +101.4% |
| FY2021 | 2021-12-31 | (8.26M) | — |
Gross Profit vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's LTM Mar 2026 gross profit of $0 is the 3rd highest of the 8 companies compared; the peer median is -$3.64K.
- Its year-over-year change of +100.0% is the 2nd highest of 6, against a peer median of +75.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.58M | +289.3% | — | 52.1% | |
| LTM Mar 2026 | $7.43M | -34.0% | -31.7% | 99.1% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| LTM Mar 2026 | -$876 | +75.7% | — | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | -$3.64K | +98.7% | — | — |
| LTM Mar 2026 | -$15K | -266.7% | — | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$42.29K | — | — | — |
| LTM Mar 2026 | -$129K | — | — | — | |
| Peer median (excluding IKT) | -$3.64K | +75.7% | -31.7% | 75.6% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.1M | 123.44K | 260.5K | 0 | 0 |
| Cost of Revenue | 11.36M | 6.72K | 13.62M | 26.27K | 0 |
| Gross Profit | (8.26M) | 116.72K | (13.36M) | (26.27K) | 0 |
| Gross Margin | -266.4% | 94.6% | -5127.8% | — | — |
| Research & Development | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M |
| Selling, General & Admin | 0 | 6.21M | 6.73M | 11.38M | 23.56M |
| Operating Expenses | 6.51M | 18.25M | 6.73M | 28.56M | 51.97M |
| Depreciation & Amortization | 14.77M | 6.72K | 177.4K | 26.27K | 60.5K |
| EBITDA | 0 | (18.05M) | (18.85M) | (27.49M) | (53.29M) |
| EBITDA Margin | 0.0% | -14620.4% | -7236.7% | — | — |
| Operating Income | (14.77M) | (18.13M) | (20.09M) | (28.59M) | (51.97M) |
| Operating Margin | -476.2% | -14686.2% | -7712.0% | — | — |
| Interest Income | 19.92K | 74.45K | 1.06M | 1.07M | 3.72M |
| Interest Expense | 19.92K | 74.45K | 0 | 0 | 0 |
| Other Income / Expenses | (19.92K) | 74.45K | 1.06M | 1.07M | 3.72M |
| Income Before Tax | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Pre-Tax Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Net Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| EPS (Basic) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| EPS (Diluted) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| Weighted Avg Shares | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
| Weighted Avg Shares (Diluted) | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.